Lyell Immunopharma Reconciled Depreciation Over Time
| LYEL Stock | USD 0.61 0.03 5.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lyell Immunopharma Performance and Lyell Immunopharma Correlation. Lyell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Reconciled Depreciation Analysis
Compare Lyell Immunopharma and related stocks such as Cullinan Oncology LLC, Monte Rosa Therapeutics, and Theseus Pharmaceuticals Reconciled Depreciation Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGEM | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 70 K | 62 K | 53 K | 93 K | 310 K | 356.5 K | 374.3 K |
| GLUE | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 537 K | 2.1 M | 3.7 M | 5.4 M | 6.3 M | 6.6 M |
| RVMD | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.8 M | 3.3 M | 6.5 M | 7.3 M | 9.7 M | 9.3 M | 10.7 M | 6.1 M |
| NKTX | 183.2 K | 183.2 K | 183.2 K | 183.2 K | 183.2 K | 183.2 K | 183.2 K | 183.2 K | 183.2 K | 400.6 K | 786 K | 1.8 M | 2.6 M | 4.3 M | 5 M | 5.2 M |
| GBIO | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 1.9 M | 3.4 M | 4.5 M | 5.1 M | 5.3 M | 6.1 M | 3.8 M |
| SANA | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 5.9 M | 11.1 M | 15.6 M | 24.6 M | 28.2 M | 29.7 M |
| NUVB | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 184 K | 199 K | 222 K | 255.3 K | 194.7 K |
| IPSC | 249 K | 249 K | 249 K | 249 K | 249 K | 249 K | 249 K | 249 K | 249 K | 249 K | 1.4 M | 3.7 M | 8.4 M | 12.3 M | 14.2 M | 14.9 M |
| STTK | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 537 K | 618 K | 1.4 M | 3.1 M | 4.1 M | 4.7 M | 4.9 M |
| CRNX | 128 K | 128 K | 128 K | 128 K | 128 K | 128 K | 128 K | 128 K | 471 K | 887 K | 948 K | 922 K | 983 K | 1.1 M | 1.3 M | 854.4 K |
| INBX | 399 K | 399 K | 399 K | 399 K | 399 K | 399 K | 399 K | 399 K | 676 K | 1.2 M | 1 M | 1.2 M | 1.2 M | 1.2 M | 1.4 M | 1.1 M |
| MRUS | 381.5 K | 381.5 K | 381.5 K | 381.5 K | 381.5 K | 381.5 K | 381.5 K | 381.5 K | 729.8 K | 1.1 M | 1.4 M | 1.5 M | 1.3 M | 2.2 M | 2.6 M | 1.4 M |
| KRON | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 356 K | 839 K | 2 M | 2.3 M | 2.2 M | 2.6 M | 1.4 M |
| EWTX | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 185 K | 272 K | 538 K | 1.7 M | 2 M | 2.1 M |
| CCCC | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.6 M | 1.6 M | 1.5 M | 1.7 M | 2 M | 2.3 M | 1.8 M |
| MLYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 43 K | 23.6 K |
Lyell Immunopharma and related stocks such as Cullinan Oncology LLC, Monte Rosa Therapeutics, and Theseus Pharmaceuticals Reconciled Depreciation description
My Equities
My Current Equities and Potential Positions
| Lyell Immunopharma | LYEL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.61
Check out Lyell Immunopharma Performance and Lyell Immunopharma Correlation. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Lyell Immunopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.